B. Riley analyst Kalpit Patel raised the firm’s price target on Viridian Therapeutics to $46 from $40 and keeps a Buy rating on the shares. After Viridian presented data from a low dose cohort of VRDN-001, Patel said the results "surprised to the upside with unexpected clinical activity" and argues that potential efficacy superiority to competitor Tepezza is "increasingly likely."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on VRDN:
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)
- Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- ‘The Likelihood of Recession in the Next 6 Months Is Low’: Credit Suisse Suggests 2 Stocks to Buy
- Viridian Therapeutics Announces First Patient Enrolled in the ‘THRIVE’ Phase 3 Trial in Patients With Thyroid Eye Disease
- Viridian Therapeutics announces first patient enrolled in THRIVE Phase 3 trial